Navigation Links
Kiadis Pharma Reports ATIR(TM) Clinical Data, Further Supporting its Potential in Mismatched Bone Marrow Transplantations
Date:4/8/2009

AMSTERDAM, April 8 /PRNewswire/ -- Biopharmaceutical company Kiadis Pharma reported preliminary clinical data on ATIR(TM) showing its potential in mismatched bone marrow transplantations. Data was presented by the company's principal investigator Dr. Denis Claude Roy during the prestigious Presidential Symposium at the Annual European Bone Marrow Transplantation meeting (EBMT) in Goteborg, Sweden, on Monday, March 30, 2009. Only the 6 highest ranked presentations, representing the most promising new developments in the transplantation field, were selected for this Symposium.

ATIR(TM), a donor lymphocyte cell based preparation depleted of allo-reactive T-cells, is under development to prevent acute Graft versus Host Disease (GvHD) and allow for early immune reconstitution following a bone marrow transplantation with a fully mismatched (haplo-identical) donor.

Dr. Roy's presentation of clinical results from 19 end stage blood cancer patients with high risk leukemia and/or lymphoma using ATIR(TM) was very well received. These patients, each of whom did not have a matched donor available, were treated in a phase I/II dose escalating study with ATIR(TM) in a mismatched transplantation setting. No immune suppressants were used, which is in contrast to conventional transplant procedures. Nevertheless, no cases of severe grade III/IV acute GvHD occurred after ATIR(TM) infusion. Furthermore, the clinical data showed a reduction in the frequency of infectious episodes in the cohorts treated with the higher doses of ATIR(TM), as compared to the low dose cohorts. To date, patients in the higher dose cohorts show high survival rates (75%) with no transplant related mortality (TRM).

These results show that the selective depletion of allo-reactive T-cells in the ATIR(TM) cell based product by the proprietary photo-sensitizing agent TH9402 is highly effective and can result in fast and adequate immune reco
'/>"/>

SOURCE Kiadis Pharma
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Kiadis Pharma Appoints Dr. Maarten Egeler, MD PhD as Chief Medical Officer
2. Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
3. EMEA Grants Kiadis Pharma Lead Product ATIR(TM) Orphan Drug Designation
4. Kiadis Pharma Receives Orphan Drug Designation for Rhitol(TM) From the FDA
5. Kiadis Pharma Reports Successful End of Phase II Meeting With FDA for Reviroc
6. Pharmatech Oncology Selected to Present at Company Showcase at BIOZONA
7. Biostar Pharmaceuticals, Inc. Reports Record Revenues and Earnings for 2008
8. Intrasphere Technologies Releases Version 1.5 of Its PharmaCM Clinical Trial Registration Solution Powered by Microsoft
9. New Pharmaxis Board Appointment
10. Pharmaxis Investor Conference Call
11. Gemin X Pharmaceuticals Selects and Deploys Clinical Force CTMS
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... Imagine being able to probe ... of others. Being able to read faces and enjoy ... to anticipate their thoughts and actions like never before. ... to create unique abstract paintings and video, or, play ... a first-person-shooter as it creates action, dialog, and outcomes ...
(Date:5/21/2015)... 2015 As part of its philanthropic ... Sun Health Foundation funded a $3.25 million project to ... with the most up-to-date features and technology. , The ... pharmacy's 45 staff members will begin moving from the ... the coming days. , The current pharmacy has ...
(Date:5/21/2015)... PA (PRWEB) May 21, 2015 ... has joined the firm as senior statistician and Principal, ... years of experience in the management and analysis of ... pharmaceutical and chemical industries. , “We’re delighted to have ... capabilities in data analytics,” said Dr. Philippe Cini, Group ...
(Date:5/20/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/qfxkcq/global_cell ... Cell Therapy Market Outlook 2020 " report to ... tissue and regenerative medicine is expected to have huge ... could help in the growth of deregulated organs. Several ... are unable to form new tissue or sometimes organ ...
Breaking Biology Technology:5 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3Julia O’Neill Joins Tunnell Consulting’s Operational and Process Improvement Practice 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 2Global Cell Therapy Market Outlook 2015-2020 - 262 Cell Therapies & 13 Marketed Cell Therapies 3
... have developed a new type of small-scale electric power ... stretching and releasing of zinc oxide wires encapsulated in ... , The new "flexible charge pump" generator is ... current by using the piezoelectric properties of zinc oxide ...
... 7 In refusing to a request for ... replacement of its,current directors, management of Trinity Biotech ... manufacturer of diagnostic products whose,American Depository Receipts ("ADRs) ... preservation of their jobs and positions in the ...
... BRISBANE, Calif., Nov. 7 InterMune, Inc.,(Nasdaq: ITMN ... Officer and President of InterMune, will present at Deutsche,Bank,s ... 4:00 p.m. EST., To access a live audio ... log on to the investor relations page of InterMune,s,corporate ...
Cached Biology Technology:New small-scale generator produces alternating current by stretching zinc oxide wires 2New small-scale generator produces alternating current by stretching zinc oxide wires 3Trinity Biotech Management Refuses to Honor Call for a Special Meeting of Shareholders 2Trinity Biotech Management Refuses to Honor Call for a Special Meeting of Shareholders 3
(Date:5/19/2015)... 18, 2015 Fingerprint Cards (FPC) has ... FPC1145, FPC1155 and FPC1035 from one if its module partners. ... including Q3 2015 and the sensors will be used by ... values for 2015 hereby amount to 740 MSEK to date. ... 140 MSEK and a number of smaller orders not separately ...
(Date:5/14/2015)... , May 14, 2015  Verificient ... identity verification and online remote proctoring, announced ... software-as-a-service (SaaS) company and creator of the ... of the two companies will benefit from ... Canvas. As a fully integrated ...
(Date:5/8/2015)... 2015 Synaptics Inc. (NASDAQ: SYNA ), the ... of the executive management team will present at the following ... and Telecom Conference Date: May 18, 2015 Time: ... MA Cowen and Company Technology, Media ... Location: The New York Palace Hotel, New York, ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Verificient and Instructure Announce Alliance Partnership to Provide Online Proctoring for K-12 and Higher Education Institutions 2Synaptics to Present at Upcoming Investor Conferences 2
... The 2009 American Society for Microbiology (ASM) ICAAC ... M. Hohl, Assistant Professor, Vaccine and Infectious Diseases ... Professor, Division of Allergy and Infectious Diseases, University ... Health, this award recognizes early career scientists for ...
... What steps have public officials in your state or ... American adolescents who are obese has tripled in just 35 ... that make it either easy or hard for families to ... eat healthy and be physically active. LOCAL GOVERNMENT ACTIONS TO ...
... The University of Texas Health Science Center at Houston ... cardiovascular indications including heart disease may produce large amounts ... by scientists in the university,s Brown Foundation Institute of ... appear in the Sept. 15 print issue of the ...
Cached Biology News:Tackling childhood obesity at the local level -- IOM report releases Sept. 1 2Scientists help explain effects of ancient Chinese herbal formulas on heart health 2
Request Info...
Request Info...
Penicillin-Streptomycin liquid...
Streptomycin sulfate an aminoglycoside used for bacterial selection binds to the small ribosomal subunit and interferes with protein biosynthesis.21H39N7O12)2x3H2SO4Formula weight:...
Biology Products: